Abstract：Objective To explore the clinical and pathological features and the diagnosis of childhood Alport syndrome (AS). Methods A retrospective analysis was performed on clinical data of 91 children with AS. Results Hematuria was observed in all 91 patients, of whom 86 were accompanied with proteinuria. Sixty-one children with X-Linked AS (XL-AS) had positive family history. Renal biopsy was performed on 82 children. Mild to moderate mesangial proliferation was observed in 74 cases. Small amounts of immune complexes deposits in the glomerular mesangial area were observed in 48 cases. Glomerular basement membrane (GBM) attenuation, thickening and layering were observed in 53 cases by electron microscopy (EM). In 63 cases receiving renal tissue type IV collagen α3 and α5 chain immunofluorescence detection, 58 were diagnosed with AS, including 53 cases of XL-AS and 5 cases of autosomal recessive AS. In 91 cases of AS, 58 were diagnosed as AS by renal tissue type IV collagen α3 and α5 chain immunofluorescence, 21 were diagnosed by EM, one was diagnosed by skin biopsy, and 12 were diagnosed by gene detection. Six novel mutations of COL4A5 gene were found. Forty-five cases were misdiagnosed before the diagnosis of AS. Forty-one of the 45 cases received steroids and/or immunosuppressant therapy. Conclusions The clinical manifestations and pathological changes are not specific in children with AS, resulting in a higher rate of misdiagnosis. Typical lesions of GBM under EM are only observed in a part of patients. There is a high novel mutation rate of COL4A5 in the detected AS children.
CHEN Yan-Zhen,SUN Liang-Zhong,WANG Hai-Yan et al. Clinical and pathological features and the misdiagnosis of childhood Alport syndrome: a retrospective analysis of 91 cases[J]. CJCP, 2017, 19(4): 371-375.
Hudson BG, Tryggvason K, Sundaramoorthy M, et al. Alport's syndrome, Goodpasture's syndrome, and type IV collagen[J]. N Engl J Med, 2003, 348(25):2543-2556.
Savige J, Gregory M, Gross O, et al. Expert guidelines for the management of Alport syndrome and thin basement membrane nephropathy[J]. J Am Soc Nephrol, 2013, 24(3):364-375.
[4]
Savige J. Alport syndrome:its effects on the glomerular filtration barrier and implications for future treatment[J]. J Physiol, 2014, 592(Pt 18):4013-4023.
[5]
Hanson H, Storey H, Pagan J, et al. The value of clinical criteria in identifying patients with X-linked Alport syndrome[J]. Clin J Am Soc Nephrol, 2011, 6(1):198-203.
[6]
Alves FR, de A Quintanilha Ribeiro F. Revision about hearing loss in the Alport's syndrome, analyzing the clinical, genetic and bio-molecular aspects[J]. Braz J Otorhinolaryngol, 2005, 71(6):813-819.
